Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix
MELBOURNE (Australia) – 18 September 2017. Telix announces that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals as Non-Executive Directors.
Telix is pleased to announce today that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals Limited as Non-Executive Directors.
Mr. McCann will also serve in the capacity of Chairman.
Telix Co-Founder and CEO Christian Behrenbruch stated, “We are very pleased to have Kevin and Mark join the Telix board at this important time in the Company’s development. They bring a tremendous amount of experience and perspective in capital markets, corporate governance and commercial strategy.”
Founding Directors Mr. Michael Cawley (Taylor Collison Limited) and Dr. Richard Zimmermann (Chrysalium Consulting) will concurrently step down from their role as Non-Executive Directors. Dr. Zimmermann remains an adviser to the Company.
To read the full press release click here.